Quality Control Analyst Qualification SOP

In short: This illustrative SOP describes how a pharmaceutical QC laboratory can document training and assess an analyst’s ability to perform assigned tests. Use the approved analytical method and a qualification protocol with justified, method-specific criteria; the imported numerical limits are shown only as in-house examples and the three-year interval is not a regulatory requirement.

Objective and scope

Provide a controlled framework for training, evaluating, authorizing and, where needed, re-evaluating QC analysts for assigned laboratory work. Adapt the framework to the site’s roles, methods, products and quality system. It is not a universal qualification scheme, and it does not replace method validation, system suitability or product specifications.

For U.S. CGMP operations, 21 CFR 211.25(a) requires personnel covered by the regulation to have education, training and experience appropriate to their assigned functions, including training in relevant operations and current CGMP. It requires continuing CGMP training at a frequency sufficient to maintain familiarity, but does not prescribe a universal analyst qualification test or a three-year requalification interval. 21 CFR 211.25(a), current eCFR.

Responsibilities

• QC management or designated method owner: Define the methods and duties for which an analyst needs training and assessment; ensure the procedure and criteria are approved and current.
• Trainer or qualified assessor: Provide documented instruction, observe the assigned work and record the assessment against the approved protocol.
• Analyst: Complete assigned training, follow current procedures and report errors, deviations or questions promptly.
• Quality unit: Review and approve controlled qualification procedures, criteria and records as assigned by the site’s quality system.

The names, approval sequence and separation of these duties must match the current organization and document-control system.

Qualification procedure

1. Define the assigned work. Identify the test methods, instruments, sample types and records included in the analyst’s role. Prioritize training and assessment based on method complexity, risk and assigned responsibility.
2. Provide training. Train the analyst on the current procedure, applicable instrument or software, sample handling, documentation, data review and the action to take when an unexpected result or deviation occurs. Keep the training record under document control.
3. Assess competence. Use a written, pre-approved protocol to identify the task, sample or reference material, observations, calculations, expected records and acceptance criteria. Criteria should reflect the approved method and the specific purpose of the assessment.
4. Review the evidence. Compare the original data and calculations with the method and qualification protocol. Document the assessor’s review, decision, scope of authorization and any limitations.
5. Address gaps. If the defined criteria are not met, document the result and provide further instruction or supervised practice as set out in the approved procedure. Reassess before extending or restoring authorization for the affected work.
6. Maintain authorization. Record the methods or duties the analyst is authorized to perform and the evidence supporting that authorization. Reassess when the site’s approved programme identifies a need, such as a relevant method change or performance concern.

Example in-house criterion (not a pharmacopoeial requirement): The imported SOP proposes assessing new analysts for accuracy, precision and good laboratory practices, with triplicate testing using a previously analysed, coded sample. If a site adopts a coded-sample exercise, define how the sample, code key, expected result, assessor and acceptance criteria are controlled in the approved protocol.

Example in-house criterion (not a pharmacopoeial requirement): The imported SOP assigns the code format AQ-YY-001, with YY as the year and 001 as a serial number, and says the QC Manager retains the coding record. Confirm whether this format and custodian remain approved, and ensure codes are unique and any blinding needed for the assessment is preserved.

Example assessment criteria from the imported SOP

The table below preserves the source’s criteria for review. They are not universal regulatory or pharmacopoeial limits. The replicate design (the source suggests triplicate testing) and every RSD value below are example in-house criteria; the source gives no pharmacopoeial or regulatory reference for them. The approved qualification protocol must identify the method, instrument, sample, replicate design and rationale for each acceptance criterion, justified by the method’s validation data (precision, range), before an assessment begins.

Example in-house criterion (not a pharmacopoeial requirement):

The criteria above are not pharmacopoeial requirements. Use method- and product-specific requirements for each assessment. Passing an analyst assessment does not change an approved method, establish a new product specification or replace method validation or system suitability.

Reassessment, training records and forms

Example in-house criterion (not a pharmacopoeial requirement): The imported SOP says existing experienced analysts are requalified every three years and that retraining and requalification follow a job or instrument change or an investigation that identifies analyst error. It does not cite a regulatory or method basis for this schedule. Set reassessment timing and triggers in the approved programme; do not present the source’s three-year interval as a regulatory requirement.

Maintain controlled records for the training, assessment protocol, method and version, sample or reference-material identity, raw results, calculations, assessor review, decision, authorized duties and any follow-up training. The imported SOP names Annexure I (qualification record), Annexure II (coded-sample identification), Annexure III (analyst qualification card) and Annexure IV (qualification certificate). The source assigns the QC Head to final raw-data review and the QA Head to approval; keep review and approval independent of the analyst assessed. Use only current approved forms, form numbers, role titles and document owner; whether a certificate forms part of authorization is decided by the site’s training and authorization procedure.

For U.S. CGMP operations, 21 CFR 211.194(a) describes the laboratory record elements, including sample identification, method, data, calculations, results, performer attribution and a second-person review. The requirements apply where that regulation governs; other jurisdictions and site procedures may add controls. 21 CFR 211.194(a), current eCFR.

Retain batch-associated GMP records for at least 1 year after the expiry date of the respective product batch. Where EU GMP applies, retain batch documentation for at least 5 years after Qualified Person certification if that period is longer. Follow any longer period required by local law, the marketing authorisation or the approved site schedule. These periods are stated in 21 CFR 211.180(a) (current eCFR) and EudraLex Volume 4, Part I, Chapter 4, Revision 1 (2011), §4.11 (effective 30 June 2011). 21 CFR 211.180(a); EudraLex Volume 4, Chapter 4.

Frequently asked questions

Does regulation require a fixed three-year analyst requalification interval?

The cited U.S. CGMP personnel rule requires continuing training with sufficient frequency to maintain familiarity, but does not set a universal three-year analyst reassessment schedule. Follow the applicable regulations and approved site programme.

Can one RSD limit be used for every test and analyst assessment?

No. Use criteria established in the approved protocol for the specific method, product, measurement range and assessment purpose. The imported values above are example in-house criteria and must be justified by method validation data before use.

What should happen if an analyst does not meet an assessment criterion?

Document the result and follow the approved training and reassessment process. Do not extend or restore authorization for the affected work until the applicable procedure permits it.

See also

• Training of employees SOP
• QC analyst qualification SOP
• Microbiology analytical data review checklist

References

• United States, 21 CFR 211.25(a), “Personnel qualifications,” current eCFR version up to date as of 14 October 2026: official regulation.
• United States, 21 CFR 211.194(a), “Laboratory records,” current eCFR version up to date as of 14 October 2026: official regulation.
• United States, 21 CFR 211.180(a), “General requirements,” current eCFR version up to date as of 14 October 2026: official regulation.
• European Commission, EudraLex Volume 4, Part I, Chapter 4, “Documentation,” Revision 1 (2011; effective 30 June 2011), §4.11: official guidance.